Related references
Note: Only part of the references are listed.ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
Louise Bowman et al.
AMERICAN HEART JOURNAL (2018)
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks Meta-analysis of 10 Trials Involving 77 917 Individuals
Theingi Aung et al.
JAMA CARDIOLOGY (2018)
PPAR- agonists are still on the rise: an update on clinical and experimental findings
Nicola Ferri et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Niacin and heart disease prevention: Engraving its tombstone is a mistake
Harold Robert Superko et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
Nathan O. Stitziel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
Deepak L. Bhatt et al.
CLINICAL CARDIOLOGY (2017)
Non-HDL Cholesterol and Triglycerides Implications for Coronary Atheroma Progression and Clinical Events
Rishi Puri et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL)
Shari S. Bassuk et al.
CONTEMPORARY CLINICAL TRIALS (2016)
Effects of Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and Carbohydrate on Glucose-Insulin Homeostasis: A Systematic Review and Meta-analysis of Randomised Controlled Feeding Trials
Fumiaki Imamura et al.
PLOS MEDICINE (2016)
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report
Terry A. Jacobson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa for Lowering Very high triglyceridEs (EVOLVE) trial
John J. P. Kastelein et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Triglycerides and cardiovascular disease
Borge G. Nordestgaard et al.
LANCET (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Jacy Crosby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial)
Kevin C. Maki et al.
CLINICAL THERAPEUTICS (2013)
Common variants associated with plasma triglycerides and risk for coronary artery disease
Ron Do et al.
NATURE GENETICS (2013)
Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes
Stephen J. Nicholls et al.
DIABETES & VASCULAR DISEASE RESEARCH (2012)
Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis
S. Matthijs Boekholdt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
Meng Lee et al.
ATHEROSCLEROSIS (2011)
Relationships between Plasma Fatty Acid Composition and Coronary Artery Disease
Hiroshige Itakura et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
LANCET (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases
Carl J. Lavie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
Yasushi Saito et al.
ATHEROSCLEROSIS (2008)
Fasting and Nonfasting Lipid Levels Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction
Anne Langsted et al.
CIRCULATION (2008)
Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia
Roxane M. Mansouri et al.
CIRCULATION RESEARCH (2008)
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
Michael H. Davidson et al.
CLINICAL THERAPEUTICS (2007)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
The forgotten majority - Unfinished business in cardiovascular risk reduction
P Libby
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
MH Davidson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg et al.
DIABETES CARE (2005)
The Omega-3 Index: a new risk factor for death from coronary heart disease?
WS Harris et al.
PREVENTIVE MEDICINE (2004)